Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293677901> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4293677901 endingPage "6958" @default.
- W4293677901 startingPage "653" @default.
- W4293677901 abstract "In addition to the highly variable clinical presentation of acute COVID-19 infection, it can also cause various post-acute signs and symptoms. In our study, we aimed to examine the efficacy of anti-fibrotic therapy in patients who developed pulmonary fibrosis after COVID-19.In total, 15 patients who applied to the Post-Covid Outpatient Clinic between May 2021 and August 2021 and were diagnosed with COVID-19 pneumonia, and whose cough, dyspnea, exertional dyspnea and low saturation continued to be present at least 12 weeks after the diagnosis, were included in the study. Off-label pirfenidone treatment was started according to the radiological findings, pulmonary function test parameters (PFT) and 6-minute walking test (6MWT) results. The patients were followed up for 12 weeks.While all of the FVC, FVC%, FEV1, FEV1%, DLCO%, DLCO/VA%, 6MWT, and room air saturation levels were observed to increase statistically significantly in the patients at the 12th week, it was determined that there was a statistically significant decrease in the pulse level in room air (p = 0.01, 0.01, 0.01, 0.01, 0.004, 0.001, 0.002, 0.001, and 0.002, respectively). In regression analysis based on radiological scoring, it was observed that the DLCO and room air saturation levels at the 12th week of the treatment were statistically significantly higher in patients with lower scores at the beginning (p = 0.04, 0.03). In addition, it was observed that anti-fibrotic treatment, which was started in the earliest period, i.e., 12 weeks after the diagnosis, resulted in an improvement in radiological, PFT and 6MWT parameters.Patients who still had dyspnea and low saturation 12 weeks after the diagnosis, defined as chronic COVID-19, should be evaluated for anti-fibrotic therapy after the necessary radiological and PFT evaluation. Early treatment commencement brings about, besides radiological improvement, a better response obtained in PFT and 6MWT (Tab. 2, Fig. 2, Ref. 21)." @default.
- W4293677901 created "2022-08-31" @default.
- W4293677901 creator A5000595429 @default.
- W4293677901 creator A5029225504 @default.
- W4293677901 creator A5048131001 @default.
- W4293677901 creator A5053785970 @default.
- W4293677901 creator A5065733913 @default.
- W4293677901 date "2022-01-01" @default.
- W4293677901 modified "2023-09-27" @default.
- W4293677901 title "When and how important is anti-fibrotic therapy in the post-COVID-19 period?" @default.
- W4293677901 doi "https://doi.org/10.4149/bll_2022_105" @default.
- W4293677901 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36039884" @default.
- W4293677901 hasPublicationYear "2022" @default.
- W4293677901 type Work @default.
- W4293677901 citedByCount "4" @default.
- W4293677901 countsByYear W42936779012022 @default.
- W4293677901 countsByYear W42936779012023 @default.
- W4293677901 crossrefType "journal-article" @default.
- W4293677901 hasAuthorship W4293677901A5000595429 @default.
- W4293677901 hasAuthorship W4293677901A5029225504 @default.
- W4293677901 hasAuthorship W4293677901A5048131001 @default.
- W4293677901 hasAuthorship W4293677901A5053785970 @default.
- W4293677901 hasAuthorship W4293677901A5065733913 @default.
- W4293677901 hasBestOaLocation W42936779011 @default.
- W4293677901 hasConcept C126322002 @default.
- W4293677901 hasConcept C16020263 @default.
- W4293677901 hasConcept C165637977 @default.
- W4293677901 hasConcept C2777714996 @default.
- W4293677901 hasConcept C2777914695 @default.
- W4293677901 hasConcept C2778341716 @default.
- W4293677901 hasConcept C2779134260 @default.
- W4293677901 hasConcept C2779832356 @default.
- W4293677901 hasConcept C3008058167 @default.
- W4293677901 hasConcept C3018587741 @default.
- W4293677901 hasConcept C524204448 @default.
- W4293677901 hasConcept C71924100 @default.
- W4293677901 hasConcept C75603125 @default.
- W4293677901 hasConceptScore W4293677901C126322002 @default.
- W4293677901 hasConceptScore W4293677901C16020263 @default.
- W4293677901 hasConceptScore W4293677901C165637977 @default.
- W4293677901 hasConceptScore W4293677901C2777714996 @default.
- W4293677901 hasConceptScore W4293677901C2777914695 @default.
- W4293677901 hasConceptScore W4293677901C2778341716 @default.
- W4293677901 hasConceptScore W4293677901C2779134260 @default.
- W4293677901 hasConceptScore W4293677901C2779832356 @default.
- W4293677901 hasConceptScore W4293677901C3008058167 @default.
- W4293677901 hasConceptScore W4293677901C3018587741 @default.
- W4293677901 hasConceptScore W4293677901C524204448 @default.
- W4293677901 hasConceptScore W4293677901C71924100 @default.
- W4293677901 hasConceptScore W4293677901C75603125 @default.
- W4293677901 hasIssue "09" @default.
- W4293677901 hasLocation W42936779011 @default.
- W4293677901 hasLocation W42936779012 @default.
- W4293677901 hasOpenAccess W4293677901 @default.
- W4293677901 hasPrimaryLocation W42936779011 @default.
- W4293677901 hasRelatedWork W2138367492 @default.
- W4293677901 hasRelatedWork W2285871974 @default.
- W4293677901 hasRelatedWork W2340104373 @default.
- W4293677901 hasRelatedWork W2378515794 @default.
- W4293677901 hasRelatedWork W2392085925 @default.
- W4293677901 hasRelatedWork W2411042954 @default.
- W4293677901 hasRelatedWork W2555155415 @default.
- W4293677901 hasRelatedWork W2556745572 @default.
- W4293677901 hasRelatedWork W3093840479 @default.
- W4293677901 hasRelatedWork W4376226481 @default.
- W4293677901 hasVolume "123" @default.
- W4293677901 isParatext "false" @default.
- W4293677901 isRetracted "false" @default.
- W4293677901 workType "article" @default.